An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

The efficacy of anti-angiogenic therapy for cancer could be improved if tumor resistance mechanisms were better understood. In this report, Napoleone Ferrara and his colleagues uncover a tumor resistance mechanism to VEGF-neutralizing antibodies triggered by IL-17, the hallmark cytokine of TH17 cells.